Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function

Lomon So, Sung Su Yea, Jean S. Oak, Mengrou Lu, Arun Manmadhan, Qiao Han Ke, Matthew R. Janes, Linda V. Kessler, Jeff M. Kucharski, Lian Sheng Li, Michael B. Martin, Pingda Ren, Katti A. Jessen, Yi Liu, Christian Rommel, David A. Fruman

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known. Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo. Conclusion: Selective inhibition of p110α preserves lymphocyte function. Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.

Original languageEnglish (US)
Pages (from-to)5718-5731
Number of pages14
JournalJournal of Biological Chemistry
Volume288
Issue number8
DOIs
StatePublished - Feb 22 2013

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Selective inhibition of phosphoinositide 3-kinase p110 α preserves lymphocyte function'. Together they form a unique fingerprint.

Cite this